Toth Financial Advisory’s Spero Therapeutics SPRO Stock Holding History

Toth Financial Advisory’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-172	Closed	-$1K	–	767
2022 Q1	$1K	Hold	172	–	–	﹤0.01%	684
2021 Q4	$3K	Hold	172	–	–	﹤0.01%	620
2021 Q3	$3K	Hold	172	–	–	﹤0.01%	620
2021 Q2	$2K	Hold	172	–	–	﹤0.01%	612
2021 Q1	$3K	Buy	+172	New	+$3.03K	﹤0.01%	561
2020 Q3	–	Sell	-172	Closed	-$2K	–	598
2020 Q2	$2K	Buy	+172	New	+$1.93K	﹤0.01%	478
2019 Q4	–	Sell	-150	Closed	-$2K	–	523
2019 Q3	$2K	Buy	+150	New	+$1.58K	﹤0.01%	426

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Toth Financial Advisory's SPRO Position: Q2 2022 in Review

Toth Financial Advisory sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 172 shares — an estimated $1K sold.

Toth Financial Advisory first reported a position in SPRO in Q3 2019 and held it in 7 quarters. The position peaked at $3K in Q4 2021. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

Toth Financial Advisory reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
Toth Financial Advisory sold 172 Spero Therapeutics shares in Q2 2022, an estimated $1K.
Toth Financial Advisory first reported a position in Spero Therapeutics in Q3 2019 and held it in 7 quarters.
Toth Financial Advisory's Spero Therapeutics position peaked at $3K in Q4 2021.
79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Toth Financial Advisory's 13F filing for Q2 2022, filed 25 Jul 2022.